NEW YORK, June 12, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, a commercial-stage biopharmaceutical company, announced new data from the AUGMENT-101 trial of their menin inhibitor, Revuforj® (revumenib), during the 30th European Hematology Association Annual Congress. These findings have led to the FDA approval of Revuforj for patients with relapsed or refractory acute leukemia featuring a KMT2A translocation. Additionally, these results underpin a supplemental New Drug Application (NDA) submitted to the FDA for treating relapsed or refractory mutant NPM1 acute myeloid leukemia $(AML.AU)$, addressing a significant unmet medical need.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.